The Record
Source documents
This is the underlying record for drgoodenowefightsforhealth.ca, a public archive of primary source documents. Each entry presents the original document alongside a full transcription or summary, so that readers can review the source material directly and reach their own conclusions from it.
-
Letter from OMQ Law to Ministers Cockrill and McLeod regarding Bill 55, The Medical Profession Amendment Act, 2026: Formal Objection to Process, Demand of On-The-Record Responses to Bill Application Questions, and Request for Amendments
OMQ Law, 401 Bay Street, 16th Floor, Toronto, Ontario M4H 2Y4
On May 5, 2026, David Moon of OMQ Law, Canadian counsel to Dr. Dayan Goodenowe and Lakeview Regional Wellness Centre Inc. (LRWC), wrote to Saskatchewan Health Minister Jeremy Cockrill and Justice Minister and Attorney General Tim McLeod regarding Bill 55, The Medical Profession Amendment Act, 2026. The letter was sent for four stated purposes: to register a formal objection to the process by which Bill 55 had advanced through committee, to identify concerns regarding the breadth and potential application of the bill, to demand formal on-the-record responses to specific questions relating to the implementation of Bill 55, and to request that the Government pause, clarify, and amend the bill before it proceeded further or before any expanded enforcement powers came into force. The letter requested a written response by 5:00pm on Friday, May 8, 2026.
-
Letter from Dr. Goodenowe to Ministers Cockrill, McLeod, and Carr regarding Bill 55, The Medical Profession Amendment Act, 2026
Dr. Dayan Goodenowe, Founder, Lakeview Regional Wellness Centre Inc. dba Dr. Goodenowe Restorative Health Centre, Moose Jaw, Saskatchewan
On April 19, 2026, Dr. Goodenowe wrote to Saskatchewan Health Minister Jeremy Cockrill, Justice Minister Tim McLeod, and Minister of Mental Health and Addictions, Seniors, and Rural and Remote Health Lori Carr, formally opposing Bill 55, The Medical Profession Amendment Act, 2026 in its present form. The letter raises three concerns with the bill as drafted, including overbreadth under Section 7 of the Charter, the delegation of investigative and prosecutorial powers to the College of Physicians and Surgeons of Saskatchewan, and practical effects on community wellness programs. The letter sets out eight proposed amendments that would address the government's public safety objectives through narrower means.
-
Statement of Claim: Goodenowe and Lakeview Regional Wellness Centre v. Beck and Clarke
Court of King's Bench for Saskatchewan, Judicial Centre of Regina. Court file number KBG-RG-00302-2026.
On April 15, 2026, Dr. Dayan Goodenowe and Lakeview Regional Wellness Centre Inc. filed a Statement of Claim in the Court of King's Bench for Saskatchewan naming Carla Beck, Leader of the Official Opposition, and Jared Clarke, MLA for Regina Walsh Acres, as defendants in an action alleging defamation and false light. The filing is the plaintiffs' pleading and sets out the allegations to be determined by the court. A Statement of Defence has not yet been filed; nothing in the claim has been proven or tested in court. The full 27-page pleading is available via the original document.
-
Lenczner Slaght letter to Candice Grant and Geoff Leo regarding CBC inquiries
Lenczner Slaght LLP, Toronto, on behalf of Dr. Dayan Goodenowe and Lakeview Regional Wellness Centre Inc.
On March 24, 2026, Brian Kolenda of Lenczner Slaght LLP responded on behalf of Dr. Goodenowe to the ten questions posed by Geoff Leo of CBC News on March 20, 2026. The letter was sent to Candice Grant of Robertson Stromberg LLP, counsel for CBC, and copied to Mr. Leo directly. It sets out the plaintiffs' response to the factual questions raised, including the historical affairs of Phenomenome Discoveries Inc. and Golden Opportunities Fund's carrying value of $133.5 million in its February 28, 2015 semi-annual report, the IND filings for PPI-1011, the ownership of 4089074 Manitoba Ltd., and the distinction between the Alzheimer's and RCDP clinical programs. It also sets out document preservation expectations in view of the ongoing litigation.
-
Email from Geoff Leo to Dr. Goodenowe requesting responses to questions for a forthcoming story
Geoff Leo, Senior Investigative Reporter, CBC News
On March 20, 2026, CBC Senior Investigative Reporter Geoff Leo emailed Dr. Goodenowe with ten questions concerning financial history, the 2007-2009 Saskatchewan government investment in Phenomenome Discoveries Inc., the planned Moose Jaw clinical trials and drug manufacturing facilities, the China initiative announced in October, and statements from a 2015 affidavit regarding clinical trials for the RCDP program. Mr. Leo set a deadline of end of day Tuesday, March 24, 2026. The response on behalf of Dr. Goodenowe was provided by Lenczner Slaght LLP on March 24, 2026.
-
FDA acknowledgement of Prodrome Sciences USA compliance response
U.S. Food and Drug Administration, Center for Drug Evaluation and Research
On March 19, 2026, the FDA's Center for Drug Evaluation and Research acknowledged Prodrome Sciences USA's January 29 response to observations from an inspection conducted between December 17, 2024 and January 10, 2025. The letter confirms that the corrective actions described in Prodrome's response are adequate to bring the company into compliance with FDA regulations, and that the correspondence is entered as a permanent part of Prodrome's regulatory file.
-
OMQ Law letter to Jared Clarke regarding public statements about Dr. Goodenowe and Lakeview Regional Wellness Centre
OMQ Law, Toronto, on behalf of Dr. Dayan Goodenowe and Lakeview Regional Wellness Centre Inc.
On March 4, 2026, counsel for Dr. Goodenowe and Lakeview Regional Wellness Centre wrote to Jared Clarke, MLA for Regina Walsh Acres, concerning statements Mr. Clarke made between December 1 and 3, 2025 on Facebook, in media interviews, and through the public release of his December 2 letter to the Moose Jaw Police Service. The letter sets out the plaintiffs' position that the statements were defamatory, demands their removal and a public retraction, and indicates that formal legal action would be prepared if the matter was not resolved by March 20, 2026. As a demand letter, it represents the position of the plaintiffs' counsel at the time of writing.
-
Draft Statement of Defence: Yolbolsum Canada Inc., Prodrome Sciences Inc., Prodrome Health Centers Inc., Dayan Goodenowe, et al., in response to Med-Life Discoveries LP
Draft prepared in response to Med-Life Discoveries LP's Statement of Claim, Court of Queen's Bench for Saskatchewan, Court File Q.B. No. 839 of 2019. This is a draft, not the version filed with the court.
This document is a draft Statement of Defence prepared for the defendants in response to the Statement of Claim filed by Med-Life Discoveries LP on June 7, 2019. Dr. Goodenowe has stated that the version ultimately filed with the court contains less detail than this draft, and that he does not retain a copy of the filed version. The draft references events through April 10, 2019. The document sets out the defendants' position on the chain of intellectual property ownership between YBCI, PDI, and Med-Life, the terms of the Non-Competition and Intellectual Property Agreement, the timing of Prodrome's research equipment acquisitions and methods development, and the defendants' response to each of the plaintiff's allegations. As a draft pleading, it represents the defendants' position as set out by their counsel at the time of drafting.
-
Statement of Claim: Med-Life Discoveries LP v. Yolbolsum Canada Inc., Prodrome Sciences Inc., Prodrome Health Centers Inc., Dayan Goodenowe, et al.
Court of Queen's Bench for Saskatchewan, Judicial Centre of Saskatoon. Court file number Q.B. No. 839 of 2019.
On June 7, 2019, Med-Life Discoveries LP, by its general partner Med-Life Discoveries GP Inc., filed a Statement of Claim in the Court of Queen's Bench for Saskatchewan naming Yolbolsum Canada Inc., Prodrome Sciences Inc., Prodrome Health Centers Inc., Dr. Dayan Goodenowe, and thirteen additional defendants comprising senior management, staff, and advisors of Prodrome and Prodrome Health Centers. The plaintiff alleged breach of contract, trespass to chattels, conversion, conspiracy, unlawful means tort, and unjust enrichment in connection with Prodrome's diagnostic tests and plasmalogen precursor research, and sought damages in excess of ten million dollars, aggravated and punitive damages, injunctive relief, an accounting of Prodrome's revenues, disgorgement, and a constructive trust over the assets of Prodrome and PHCI. The filing is the plaintiff's pleading and sets out the allegations to be determined by the court. Nothing in the claim has been proven or tested in court.
-
Statement of Claim: Yolbolsum Canada Inc. v. Golden Opportunities Fund Inc. et al.
Court of Queen's Bench for Saskatchewan, Judicial Centre of Saskatoon. Court file number Q.B.G. No. 1692 of 2018.
On October 24, 2018, Yolbolsum Canada Inc. (YBCI), Dr. Goodenowe's holding company and the majority shareholder of Phenomenome Discoveries Inc. (PDI), filed a Statement of Claim in the Court of Queen's Bench for Saskatchewan against Golden Opportunities Fund Inc., Grant Kook, Douglas Banzet, Peter Blaney, Barry Markowsky, L. David Dube, Concorde Centres Inc., PIC Investment Group Inc., Med-Life Discoveries LP, and twelve other defendants. The claim sought damages estimated to be greater than $400 million in connection with the PDI receivership and the acquisition of PDI's assets by Med-Life Discoveries. The action did not proceed on the merits: it was dismissed on the basis that YBCI lacked standing to bring the claim. As a result, none of the allegations in this pleading were tested or adjudicated. The filing remains in the public court record and sets out the facts the plaintiff would have sought to prove had the action proceeded.
-
Dr. Goodenowe's October 2016 written account of the Phenomenome receivership
Prepared during the Yolbolsum Canada Inc. v. Golden Opportunities Fund Inc. proceedings
Dr. Goodenowe's October 2016 written account of the Phenomenome receivership, prepared during the Yolbolsum v. Golden Opportunities Fund proceedings.
-
AlzID Program Highlights: Alzheimer's Disease Risk Blood Test (Phenomenome Discoveries Inc., March 2016)
Phenomenome Discoveries Inc., 204-407 Downey Road, Saskatoon, Saskatchewan.
A two-page product overview prepared by Phenomenome Discoveries Inc. in March 2016 describing AlzID, a blood test measuring three ethanolamine plasmalogens and one phosphatidylethanolamine combined into a single quantitative value called the Plasmalogen Biosynthesis Value (PBV). The document states that AlzID was approved for use in Canada by Health Canada and that patents were issued across multiple jurisdictions including Canada, the United States, and several European countries, with expiry on February 28, 2027. It references a NIH-sponsored longitudinal study at Rush University in Chicago involving over 1,000 elderly subjects and the NIH-sponsored Alzheimer's Disease Neuroimaging Initiative, both described in the document as showing associations between higher PBV and lower Alzheimer's disease risk.
-
Cologic Program Highlights: Colorectal Cancer Risk Blood Test (Phenomenome Discoveries Inc., March 2016)
Phenomenome Discoveries Inc., 204-407 Downey Road, Saskatoon, Saskatchewan.
A product overview prepared by Phenomenome Discoveries Inc. in March 2016 describing Cologic, a blood test measuring levels of the metabolite GTA-446 as a risk factor for colorectal cancer. The document states that Cologic was approved for use in Canada by Health Canada, that it had been evaluated in a prospective clinical trial involving 5,000 colonoscopy subjects and 1,000 population controls at two hospitals in Saskatchewan over a two-year period, and that post-market surveillance of approximately 15,000 Cologic customers in Canada over a two-year period yielded a positive predictive value of 2.9 percent. The test was performed at Phenomenome Laboratory Services Inc., a laboratory in Saskatoon certified by the College of American Pathologists and the College of Physicians and Surgeons of Saskatchewan.
-
OvAware Program Highlights: Ovarian Cancer Risk Blood Test (Phenomenome Discoveries Inc., March 2016)
Phenomenome Discoveries Inc., 204-407 Downey Road, Saskatoon, Saskatchewan.
A product overview prepared by Phenomenome Discoveries Inc. in March 2016 describing OvAware, a blood test measuring ratios among eight lipids in the blood as a risk factor for ovarian cancer. At the time of writing, OvAware was pending approval by Health Canada and other regulatory bodies, and was run as a research-use-only laboratory-developed test at Phenomenome Laboratory Services Inc. The document describes validation studies including a Japanese cohort of 122 ovarian cancer patients and 96 controls, and a Canadian validation involving 234 ovarian cancers, 62 endometrial cancers, and over 600 control female samples.
-
PanaSee Program Highlights: Pancreatic Cancer Risk Blood Test (Phenomenome Discoveries Inc., March 2016)
Phenomenome Discoveries Inc., 204-407 Downey Road, Saskatoon, Saskatchewan.
A product overview prepared by Phenomenome Discoveries Inc. in March 2016 describing PanaSee, a blood test measuring levels of the metabolite PC-594 as a risk factor for pancreatic cancer. The document states that PanaSee was approved for use in Canada by Health Canada and that the test detects approximately 86 percent of existing pancreatic cancers, independent of stage. It describes multiple validation studies conducted in Japan and North America, and identifies the test as performed at Phenomenome Laboratory Services Inc., a laboratory in Saskatoon certified by the College of American Pathologists and the College of Physicians and Surgeons of Saskatchewan.
-
The Phenomenome Clinical Analyzer Platform: Asset Summary (Phenomenome Discoveries Inc., circa 2016)
Phenomenome Discoveries Inc., 204-407 Downey Road, Saskatoon, Saskatchewan.
A two-page asset summary prepared by Phenomenome Discoveries Inc. describing the Phenomenome Clinical Analyzer Platform, an integrated mass spectrometry system designed to process up to 1,000 patient samples per day. The document states that the platform was manufactured under ISO 13485:2003 with OEM-sourced components and was FDA compliant. It identifies the four test kits intended to run on the platform: Cologic for colorectal cancer, PanaSee for pancreatic cancer, AlzID for Alzheimer's disease risk, and OvAware for ovarian cancer, the last described as in production at time of writing.